Trenton, N.J. (PRWEB) April 30, 2013
A New Jersey jury ruled in favor of pharmaceutical company Merck in a Fosamax femur fracture trial in Trenton on April 29.* The Rottenstein Law Group, which represents clients in Fosamax lawsuits, encourages those who seek to file lawsuits to continue to do so, despite the ruling in what was considered a bellwether trial for Fosamax femur fracture side effects. The firm maintains a Fosamax Lawsuit Information Center at http://www.rotlaw.com/fosamax, which has more information on trials and side effects and how to file a Fosamax lawsuit.
“Though the verdict did not favor the plaintiff, there is no reason for the Fosamax plaintiffs across the nation to be discouraged,” said Rochelle Rottenstein, principal of the Rottenstein Law Group.
Bernadette Glynn, 58, sued Merck, asserting that it knew Fosamax could cause femur fractures and brittle bones years before the drug went to market, according to Bloomberg. The jury found that Glynn’s injuries ruled out Fosamax as a cause. Instead, the jury ruled that Glynn’s femur fracture was consistent with a traumatic injury (Glynn v. Merck & Co., 3:11-cv-05304, U.S. District Court for the District of New Jersey).
New Jersey-based Merck faces more than 3,000 femur fracture lawsuits (in addition to more than 1,200 lawsuits over jawbone death claims), according to Bloomberg.
Fosamax, its generic equivalent and other similar bisphosphonate drugs are prescribed to treat osteoporosis. In 2010, according to Bloomberg, a study published in the Journal of Bone and Mineral Research found that the drug, approved in 1995, could be linked to an increase in femur fractures.
Nationwide Fosamax lawsuits were categorized into two different federal pretrial case consolidations for efficiency purposes. Cases involving alleged femur fractures are handled in the
Copyright©2012 Vocus, Inc.
All rights reserved